Clarity Pharmaceuticals (ASX:CU6) has announced the appointment of Jon Stoner, the world leading expert in copper-67 isotope (Cu-67 or 67Cu) production, to its Scientific Advisory Board.
The clinical-stage radiopharmaceutical company says Mr Stoner is the director of the Idaho Accelerator Center (IAC) and has over 10 years of experience in production of the copper-67 isotope.
It also says Mr Stoner has 3 patents and 11 related publications.
Clarity Pharmaceuticals is focused on developing next-generation products to improve treatment outcomes for children and adults with cancer and Stoner's expertise will help them progress their clinical trials and move towards high-volume manufacture of copper-67.